Drugs / GSK4527363
last change Sep 2024 re-read 2 minutes ago

GSK4527363

Developed for
systemic lupus erythematosus
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

2025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06576271 Sep 2024 → Jan 2028 expected systemic lupus erythematosus GlaxoSmithKline Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GSK4527363 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06576271